Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Oruka Therapeutics, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kodiak Sciences (KOD) and Oruka Therapeutics (ORKA) ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released yesterday, David Nierengarten from Wedbush initiated coverage with a Buy rating on Oruka Therapeutics and a price target of $1...

Oruka Therapeutics (ORKA) Has a New Rating from Wedbush

In a report released today, Roger Song from Jefferies maintained a Buy rating on Oruka Therapeutics, with a price target of $133.00. According to T...

Jefferies Keeps Their Buy Rating on Oruka Therapeutics (ORKA)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Oruka Therapeutics today and set a price target of $180.00. Rahimi covers the Healt...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORKA	$112.66	+1.46%	514.81K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ORKA	$112.66	+1.5%	514.81K
3
4
5
6

ORKA

Get Oruka Therapeutics, Inc. Data in Excel

Get Oruka Therapeutics, Inc. Data in Excel